Pedro Freitas

7PUBLICATIONS
17CO-AUTHORS
Predictive and prognostic markersOther creative arts and writing not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNeurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 17, 2025
4K density: Adjusting the 4Kscore for prostate volume to improve risk stratification of clinically significant prostate cancer in men undergoing prostate biopsy.

Timothy Guerard, Joao G Porto, Thomas Fekete

|Jul 22, 2025
Reply by Authors.

Pedro F S Freitas, Archan Khandekar, Joao G Porto

|Jun 20, 2025
Can Genomic Classifiers in Biopsy Cores With Grade Group 1 Cancer Predict Higher-Grade Disease Elsewhere in the Prostate? Results From the Prospective Miami Active Surveillance Trial.

Pedro F S Freitas, Archan Khandekar, Joao G Porto

|Feb 22, 2025
Cabazitaxel versus abiraterone or enzalutamide for metastatic castration-resistant prostate cancer following docetaxel failure: a systematic review and meta-analysis.

Izael Pereira da Silva, Lucas Guimarães Campos Roriz de Amorim, Gabriel Vieira Piredda

|Nov 14, 2024
HSD3B1, prostate cancer mortality and modifiable outcomes.

Pedro F S Freitas, Alireza Abdshah, Rana R McKay

|Sep 30, 2024
Changing times: trends in risk classification, tumor upstaging, and positive surgical margins after radical prostatectomy - results from a contemporary National Cancer Database study.

Pedro F S Freitas, Ruben Blachman-Braun, Nachiketh Soodana-Prakash

Pageof 2

Frequent Collaborators

2 joint publications

Oleksandr N Kryvenko

2 joint publications

Hui Yu

2 joint publications

Joao G Porto

1 joint publications

Chad Ritch